BioBusiness

Articles

In their collaboration, Bristol Myers Squibb and Prellis Biologics aim to generate human antibody libraries for select targets to enable drug discovery.

Bristol Myers Squibb and Prellis Biologics Partner to Build Human Antibody Libraries

Fosun Pharma and Insilico Medicine will collaborate on AI-driven drug discovery and development of product candidates targeting multiple disease targets.

Fosun Pharma and Insilico Medicine Partner on Drug Discovery and Development Using Artificial Intelligence

The collaboration between Bristol Myers Squibb and Century Therapeutics will combine Century’s iPSC-derived allogeneic cell therapy platform with Bristol Myers Squibb’s expertise in cell therapy and oncology drug development.

Bristol Myers Squibb and Century Therapeutics to Collaborate on Developing iPSC-derived Allogeneic Cell Therapies

Luc Gagnon, PhD, is vice-president of Vaccine Sciences at Nexelis.

The COVID-19 pandemic generated partnerships among organizations with the goal of changing the way in which assay development and tech transfer of these assays are conducted moving forward.

Elements that are Key for Successful Assay Transfer

Feliza Mirasol is the science editor for 

The urgency with which COVID-19 forced the biopharma industry to produce therapies has refocused the search for new tools to enable rapid therapeutic responses to a pandemic.

COVID Pandemic Prompts Renewed Interest in Biotech Startups

GlaxoSmithKline, together with the University of Oxford, has launched the Oxford-GSK Institute under a new collaboration that aims to study complex diseases to accelerate the success of drug discovery and drug development efforts.

GSK and University of Oxford Partner on Disease Research to Advance Drug Discovery and Development

Lonza has signed a five-year services agreement to provide for the development and manufacturing of biologics and small molecules for portfolio companies owned by Bioqube Ventures.

Lonza and Bioqube Ventures Form Agreement for Future Development and Manufacture of Biologics and Small Molecules

Leucid Bio will collaborate with Lonza to use Lonza’s Cocoon Platform for clinical and commercial manufacturing of CAR T cells for Leucid’s lead candidate.

Leucid Bio to Use Lonza’s Cocoon Platform for Automated Manufacturing of CAR T Cells

Chinook Therapeutics has formed a 50/50 joint venture with investors to develop kidney disease therapies in China.

Chinook Therapeutics and Investors Form Joint Venture for Kidney Disease Therapies

Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers that should continue in the future.